R and D Related Headlines
Go Back- Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related
- Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
R and D Related Press Releases
Go Back- Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related
- Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
